

PROVINCIAL FUNDING SUMMARY

Lenalidomide (Revlimid) for Multiple Myeloma

pERC Recommendation: Recommend with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: Nov 6, 2013

This information is current as of March 29, 2016. The use of this document is directed by [pCODR's Terms of Use](#).

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs and cancer agencies for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Jan 1, 2015	Maintenance treatment for patients with newly diagnosed multiple myeloma, following autologous stem cell transplant; Minimum of stable disease post transplant; A BC Cancer Agency "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment.
AB	Funded	Sep 30, 2014	As a maintenance treatment for patients with newly diagnosed multiple myeloma following autologous stem cell transplantation. Feb 3, 2016: Concurrent use with bortezomib maintenance for high risk patients with any of the del 17p, t(14:16) is approved
SK	Funded	Sep 15, 2014	As maintenance treatment for patients with newly diagnosed multiple myeloma following autologous stem cell transplant (ASCT) in patients with stable disease or better, with no evidence of disease progression
MB	Funded	Oct 16, 2014	Maintenance treatment for patients with newly diagnosed Multiple Myeloma following autologous stem-cell transplantation (Post-ASCT): <ul style="list-style-type: none"> • Patients with stable disease or better, with no evidence of disease progression; • Treat until progression or development of unacceptable toxicity requiring discontinuation of lenalidomide; • Initial dose of 10 mg lenalidomide daily; and • Dose adjustments (5-15 mg) may be necessary based on individual patient characteristics/responses.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	Sep 9, 2014	<p>Initial requests: For the maintenance treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation (ASCT) who have stable disease or better, with no evidence of disease progression</p> <p>Approval duration: 1 year Recommended Dosage: Initial dose of 10 mg daily Dose adjustments (5-15 mg) may be necessary based on individual patient characteristics/responses</p> <p>Renewals: Lenalinomide may be continued until evidence of disease progression or development of unacceptable toxicity requiring discontinuation of lenalidomide Approval duration: 1 year</p>
NS	Funded	Dec 29, 2014	<p>For the maintenance treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation (ASCT):</p> <ul style="list-style-type: none"> - in patients with stable disease or better, with no evidence of disease progression; - treat until progression or development of unacceptable toxicity requiring discontinuation of lenalidomide; - initial dose 10 mg lenalidomide PO daily, AND - dose adjustments (5-15 mg) may be necessary based on individual patient characteristics/responses
NB	Funded	Dec 12, 2014	<p>For the maintenance treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation (ASCT), who have stable disease or better, with no evidence of disease progression.</p> <p>Renewal criteria:</p> <ul style="list-style-type: none"> • Written confirmation that there is no evidence of disease progression. <p>Clinical Notes:</p> <ul style="list-style-type: none"> • Recommended Dose: Initial dose of 10 mg daily. Dose adjustments (5-15 mg) may be necessary based on individual patient characteristics/responses. • Lenalinomide may be continued until evidence of disease progression or development of unacceptable toxicity requiring discontinuation of lenalidomide. Claim Notes: • Initial approval duration: 1 year • Renewal approval duration: 1 year

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
NL	Funded	Dec 1, 2014	<p>Newly diagnosed Multiple Myeloma following autologous stem-cell transplantation (ASCT):</p> <ul style="list-style-type: none"> • For maintenance treatment • Patients with stable disease or better, with no evidence of disease progression • Treat until progression or development of unacceptable toxicity requiring discontinuation of lenalidomide <p>Initial Approval Period: 3 months Initial dose: 10mg daily AND dose adjustments may be necessary based on individual patient characteristics/responses</p> <p>Renewals will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of lenalidomide. Renewal Approval Period: 12 months</p>
PEI	Funded	Nov 23, 2015	<p>For the Maintenance Treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation (ASCT), in patients who: are with stable disease or better, with no evidence of disease progression; treat until progression or development of unacceptable toxicity requiring discontinuation of lenalidomide; initial dose 10mg lenalidomide PO daily, AND dose adjustments (5-15mg) may be necessary based on individual patient characteristics/responses.</p>